PlainPharmaWatch

CMS Open Payments · Tool

Daiichi Sankyo Company LTD vs Biotronik Inc.

Side-by-side comparison of CMS Open Payments data for Program Year 2024. Select different companies below to start a new comparison.

A larger reported total is not "better" or "worse", it is a neutral fact about disclosure volume; a reported payment documents a financial relationship, not evidence of wrongdoing.

Compare Different Companies

vs

Relationship comparison

Which recorded payment profile is more concentrated?

Daiichi Sankyo Company LTD has the more concentrated recorded General Payments recipient profile in Program Year 2024: its recipient-distribution HHI is 1,293, versus 102 for the other company. Its single largest recorded recipient represents 0.2% of that company's General Payments recipient total.

HHI summarizes how payments are distributed across recorded recipients: higher means a less evenly distributed recipient pattern. This is a description of CMS-reported General Payments only, not a finding about conduct, prescribing, quality, or wrongdoing. Read it with the recipient count and underlying records below.

Daiichi Sankyo Company LTD
HHI 1,293 · top recipient 0.2%
Ranked #923 of 1,838 companies by HHI
Biotronik Inc.
HHI 102 · top recipient 0.1%
Ranked #1,689 of 1,838 companies by HHI

Payment Overview

Total Payments
$4.6M
% of Industry
0.0%
Transactions
261
Avg per Transaction
$17.5K
Recipients
51
Avg per Recipient
$89.3K
Payment Types
4
Top Payment Type
Royalty or License
Company B

Biotronik Inc.

Total Payments
$4.5M
% of Industry
0.0%
Transactions
15,086
Avg per Transaction
$300.56
Recipients
10,399
Avg per Recipient
$436.03
Payment Types
9
Top Payment Type
Debt Forgiveness

Highlighted values indicate the higher figure for each metric.

Total payments compared

Daiichi Sankyo Company LTD vs Biotronik Inc. - total reported payments in CMS Open Payments PY2024

Daiichi Sankyo Company LTD$4.6MBiotronik Inc.$4.5M

Payment Types Breakdown

Daiichi Sankyo Company LTD

Royalty or License $159.0K

3.5%

Consulting Fee $86.6K

1.9%

Travel and Lodging $69.3K

1.5%

Food and Beverage $1.5K

0.0%

Biotronik Inc.

Debt Forgiveness $898.4K

19.8%

Food and Beverage $481.2K

10.6%

Travel and Lodging $424.1K

9.4%

Compensation for Faculty or Speaker (Medical Education) $231.1K

5.1%

Consulting Fee $203.9K

4.5%

Grant $143.0K

3.2%

Top 5 General-Payment Recipients

This list uses CMS detailed General Payments records only; it excludes research and ownership/investment records, so it does not equal the all-category totals above. A reported payment documents a financial relationship, not evidence of wrongdoing; a higher total reflects reporting volume, not conduct. Verify directly at openpaymentsdata.cms.gov.

Daiichi Sankyo Company LTD

  1. 1

    Memorial Hospital For Cancer And All

    $65,000.00 · 2 txns

  2. 2

    Hospital Of The Univ Of Penna

    $56,000.00 · 2 txns

  3. 3

    ERIKA HAMILTON

    $46,438.26 · 8 txns

  4. 4

    KOMAL JHAVERI

    $38,400.96 · 9 txns

  5. 5

    Chi St Lukes Health Baylor Med Ctr

    $30,000.00 · 2 txns

Biotronik Inc.

  1. 1

    Bayonne Medical Center

    $147,601.05 · 24 txns

  2. 2

    RON WAKSMAN

    $118,497.87 · 10 txns

  3. 3

    Scripps Green Hospital

    $40,921.07 · 17 txns

  4. 4

    GAURAV UPADHYAY

    $38,705.15 · 7 txns

  5. 5

    Washington Hospital Center

    $35,000.00 · 4 txns

Summary Comparison

Metric Daiichi Sankyo Company LTD Biotronik Inc.
Total Payments $4.6M $4.5M
% of Industry Total 0.0% 0.0%
Transaction Count 261 15,086
Avg per Transaction $17.5K $300.56
Recipient Count 51 10,399
Avg per Recipient $89.3K $436.03
Payment Type Count 4 9
Top Payment Type Royalty or License Debt Forgiveness

Data Source: Centers for Medicare & Medicaid Services (CMS) Open Payments, Program Year 2024. Data includes general payments, research payments, and physician ownership/investment interests as required by the Physician Payments Sunshine Act. All companies in the CMS Open Payments company corpus are available in the selector. Browse all companies →

Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.